Replimune Group Stock Performance
as on August 22, 2026 at 6:59 am IST
Day's Low
Day's High
$13.85$14.98
6.04%
Downside
1.63%
Upside
52 Week's Low
52 Week's High
$1.50$15.7189.82%
Downside
6.55%
Upside
Replimune Group share price movements today
- Previous Close
- $14.05
- Open
- $13.88
- Volume
- 3.0M
- Market Cap
- $1.4B
- Day's Low - High
- $13.85 - $14.98
- 52 Week Low - High
- $1.50 - $15.71
Replimune Group Historical Returns
- 1 Month Return
- + 46.33 %
- 3 Month Return
- + 186.78 %
- 1 Year Return
- + 169.24 %
- 3 Year Return
- -21.54 %
- 5 Year Return
- -50.63 %
Replimune Group Stock Fundamentals & Key Indicators
Check Replimune Group market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$1.4B
EPS (TTM)
-3.38
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.00%
PE Ratio (TTM)
-4.49
Industry PE ratio
-7.283372093023256
PEG Ratio
0.7497149149254385
EBITDA
-314.5M
Revenue (TTM)
-
Profit Margin
0.00%
Return On Equity TTM
-128.57%
Replimune Group Stock Valuation
Track how Replimune Group P/E has moved over time to understand its valuation trends.
Replimune Group in the last 5 years
Lowest (-7.51x)
March 31, 2022
Industry (-7.28x)
March 31, 2026
Today (-2.26x)
March 31, 2026
Highest (-2.26x)
March 31, 2026
Today’s Price to Earnings Ratio: -2.26x
Replimune Group stock Key Stats
Compare market cap, revenue, PE, and other key metrics of Replimune Group with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % | Dividend Yield % |
|---|---|---|---|---|---|---|
| BUY | $1.4B | -50.63% | -4.49 | 0.00% | NA |
Stock Returns calculator for Replimune Group Stock including INR - Dollar returns
The Replimune Group stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.
Investment Value
₹1,00,000
Replimune Group investment value today
Current value as on today
₹2,90,593
Returns
₹1,90,593
(+190.59%)
Returns from Replimune Group Stock
₹1,65,108 (+165.11%)
Dollar Impact
₹25,485 (+25.48%)
Analyst Recommendation on Replimune Group Stock
Based on 6 analysts
100.00%
Buy
0.00%
Hold
0.00%
Sell
Based on 6 analysts, 100% of analysts recommend a 'BUY' rating for Replimune Group. Average target price of $19.33
Replimune Group Share Price Target
Get share price movements and forecasts by analysts on Replimune Group.
What analysts predicted
23.75%UPSIDE
Target Price
$19.33
Current Price
$14.74
Analyzed by
6 Analysts
Target
$19.33
Replimune Group target price $19.33, a slight upside of 23.75% compared to current price of $14.74. According to 6 analysts rating.
Indian Investors' Interest in Replimune Group Stock
Investment in Replimune Group Shares on INDmoney has grown by 264.51% in the last 30 days, indicating increased investment activity.
Time period: to
Change:264.51% versus previous 30 day period
Search interest for Replimune Group Stock has increased by 149% in the last 30 days, reflecting an upward trend in search activity.
Time period: to
Change:149% versus previous 30 day period
Replimune Group Quarterly Profit & Loss
All numbers in Millions USD
Replimune Group Annual Profit & Loss
All numbers in Millions USD
Replimune Group Quarterly Cash Flow
All numbers in Millions USD
Replimune Group Annual Cash Flow
All numbers in Millions USD
Replimune Group News & Key Events
Today's Timeline - 28 July
Tue, 11:39 PM
-FDA deems Replimune's IGNYTE study inadequate, leading to a significant stock drop.
Wed, 04:08 AM
-Replimune shares fall 38% after FDA documents raise doubts about cancer drug approval.
Insights on Replimune Group
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTPrice Rise
In the last 3 months, REPL stock has moved up by 186.2%
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, -13.38 Cr → 0.53 Cr (in ₹), with an average increase of 2624.5% per quarter
NO EFFECTAgainst Peers
In the last 3 years, Revolution Medicines, Inc. Common Stock has given 594.2% return, outperforming this stock by 624.1%
- NO EFFECT
Against Peers
In the last 3 years, eClerx Services Ltd has given 121.7% return, outperforming this stock by 187.6%
- NO EFFECT
Retail Holding Unchanged
Retail Investor holdings remained unchanged at 31.21% of holdings in Jun 2026 quarter
- NO EFFECT
Against Peers
In the last 1 year, One 97 Communications Ltd has given 28.7% return, outperforming this stock by 91.5%
- NO EFFECT
Against Peers
In the last 1 year, Revolution Medicines, Inc. Common Stock has given 472.1% return, outperforming this stock by 324.3%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 68.64% of holdings in Jun 2026 quarter
NEGATIVE IMPACTPrice Dip
In the last 6 months, REPL stock has moved down by -29.7%
- NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 4 quarters, 22.22 Cr → 10.28 Cr (in ₹), with an average decrease of 18.6% per quarter
About Replimune Group
| Organisation | Replimune Group |
| Headquarters | 500 Unicorn Park Drive, Woburn, MA, United States, 01801 |
| Industry | Biotechnology |
| CEO | Dr. Sushil Patel Ph.D. |
| E-voting on shares | Click here to vote |
Key Management of Replimune Group
Name | Title |
|---|---|
Dr. Konstantinos Xynos M.B.A., M.D., Ph.D. | Chief Medical Officer |
Mr. Andrew Schwendenman | Chief Accounting Officer & Treasurer |
Mr. Shawn Glidden J.D. | Senior VP & General Counsel |
Ms. Carolyn Trott | Senior Vice President of Quality Assurance |
Dr. Sushil Patel Ph.D. | CEO & Director |
Mr. Philip Astley-Sparke F.S.A. | Executive Chairman |
Mr. Camilo Garcia M.A., M.B.A. | Chief Human Resource Officer |
Mr. Paul Bullock | Chief Manufacturing Officer & Framingham Site Head |
Ms. Nina Aragam | Senior Vice President of Portfolio Strategy & Program Management |
Ms. Emily Luisa Hill | Chief Financial Officer |
FAQs
What is Replimune Group share price today?
Replimune Group share price today is $14.74 as on at the close of the market. Replimune Group share today touched a day high of $14.98 and a low of $13.85.
What is the 52 week high and 52 week low for Replimune Group share?
Replimune Group share touched a 52 week high of $15.71 on and a 52 week low of $1.50 on . Replimune Group stock price today i.e. is closed at $14.74,which is 6.14% down from its 52 week high and 882.67% up from its 52 week low.
What is Replimune Group's market capitalisation today?
Replimune Group market capitalisation is $0.00T as on .
How to invest in Replimune Group Stock (REPL) from India?
- Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
- Step 2: Search for Replimune Group on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Replimune Group Shares that will get you 0.1018 shares as per Replimune Group share price of $14.74 per share as on August 22, 2026 at 1:29 am IST.
What is the minimum amount required to buy Replimune Group Stock (REPL) from India?
Indian investors can start investing in Replimune Group (REPL) shares with as little as ₹95.685 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹956.85 in Replimune Group stock (as per the Rupee-Dollar exchange rate as on ).
Based on Replimune Group share’s latest price of $14.74 as on August 22, 2026 at 1:29 am IST, you will get 0.6784 shares of Replimune Group. Learn more about
fractional shares .
What are the returns that Replimune Group has given to Indian investors in the last 5 years?
Replimune Group stock has given -50.63% share price returns and 29.07% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?